Pricing and reimbursement of innovative pharmaceuticals in France and the new healthcare reform

Pricing and reimbursement of innovative pharmaceuticals in France and the new healthcare reform

Authors

  • Alexander Natz
  • Marie-Geneviève Campion European Confederation of Pharmaceutical Entrepreneurs (EUCOPE), Brussels

DOI:

https://doi.org/10.7175/fe.v13i2.270

Keywords:

Pricing, Costs, France, Pharmaceutical

Abstract

Over the last years, many cost-containment measures were implemented by the government leading to drastic price-cuts. New paradigms and healthcare models are emerging and health technology assessments are increasingly taken into consideration. France has the second biggest rank in terms of healthcare spending after the US. Pharmaceuticals represented around 19% of the budget of the Health Insurance funds in 2009. In France, innovative pharmaceuticals have been subject for a long-time to price-control and cost-containment measures. The present review provides a general description of the French health care system, analyzing the developments and changes by the recent French health care reform.

Downloads

Published

2012-06-04

How to Cite

Natz, A., & Campion, M.-G. (2012). Pricing and reimbursement of innovative pharmaceuticals in France and the new healthcare reform. Farmeconomia. Health Economics and Therapeutic Pathways, 13(2), 49–60. https://doi.org/10.7175/fe.v13i2.270

Issue

Section

Review (Economic Analysis)

Similar Articles

<< < 4 5 6 7 8 9 10 11 12 13 > >> 

You may also start an advanced similarity search for this article.

Loading...